Robert Taub

Portfolio · 3

Nyxoah

Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea

1 round $20.0M committed Latest: 2016-07

NeuroDerm

Drug-device Combination Solutions for Central Nervous System Disorders

1 round $2.5M committed Latest: 2007-07

ARCHIMEDICX

Hospital Search, Ranking, and Booking System

1 round $1.0M committed

Investment activity

2 portfolio exits on record.

Q&A

What is Robert Taub's primary investment focus by sector?

Robert Taub primarily focuses on the Health Tech & Life Sciences sector, with all three of his portfolio companies and two exits being in this area.

Can you name some of Robert Taub's notable portfolio companies?

Robert Taub's notable portfolio companies include ARCHIMEDICX, which offers a hospital search, ranking, and booking system, and Nyxoah, focused on hypoglossal nerve stimulation therapy.

Which of Robert Taub's portfolio companies have had a public exit?

Robert Taub has seen two portfolio companies go public: Nyxoah in September 2020 on Euronext with a valuation of $423M, and NeuroDerm in November 2014 on NASDAQ with a valuation of $164M.

What is Robert Taub's investment stage preference?

Robert Taub has invested across various stages, including Seed, A Round, and B Round.

What kind of business models do Robert Taub's portfolio companies typically have?

Robert Taub's portfolio companies, such as ARCHIMEDICX, engage in both B2B and B2C business models, while others like NeuroDerm and Nyxoah focus on B2B.